scholarly journals Half and half nail, is it a marker of severe COVID-19 infection ?

2021 ◽  
Author(s):  
SORAYA AOUALI ◽  
Saida Sefraoui ◽  
nada zizi ◽  
Siham Dikhaye
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Chronic Diseases ◽  
Clinical Finding

Half and half nail or Lindsay’s nail is a rare clinical finding that can be seen in many chronic diseases, such as chronic renal failure. We report 2 cases of half and half nail aspect during severe Covid-19 infection suggesting that it can be considered as a severity marker.

scholarly journals The anemia of chronic renal failure and chronic diseases: in vitro studies of erythropoiesis

Blood ◽  
1976 ◽  
Vol 47 (4) ◽  
pp. 561-569
Author(s):  
SF Wallner ◽  
JE Kurnick ◽  
HP Ward ◽  
R Vautrin ◽  
AC Alfrey
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Human Serum ◽  
Chronic Diseases ◽  
Normal Serum ◽  
Severe Anemia ◽  
Serum Factor ◽  
Heme Synthesis ◽  
Guanidinosuccinic Acid

The presence of a serum factor in chronic renal failure (CRF) which inhibits erythropoietin-stimulated erythropoiesis was studied, using a technique in which dog marrow cells were stimulated to produce heme in the presence of human serum. In the total series comparing 27 normal sera with 52 CRF sera, less heme was synthesized when the system contained CRF sera (total series, p = 0.0001). There was no evidence of inhibition of heme synthesis by serum from 12 patients with the anemia of chronic diseases (CD). Mixing experiments with normal and CRF sera suggested that this defect in CRF serum was not due to lack of a factor necessary for heme synthesis. Addition of urea, creatinine, and guanidinosuccinic acid to normal serum did not impair its ability to support erythropoiesis in this system. These data demonstrated that serum from patients with CRF contains a material inhibiting erythropoiesis in vitro, We propose that the material is responsible, in part, for the clinically severe anemia seen in these patients.

scholarly journals The anemia of chronic renal failure and chronic diseases: in vitro studies of erythropoiesis

Blood ◽  
1976 ◽  
Vol 47 (4) ◽  
pp. 561-569 ◽  
Author(s):  
SF Wallner ◽  
JE Kurnick ◽  
HP Ward ◽  
R Vautrin ◽  
AC Alfrey
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Human Serum ◽  
Chronic Diseases ◽  
Normal Serum ◽  
Severe Anemia ◽  
Serum Factor ◽  
Heme Synthesis ◽  
Guanidinosuccinic Acid

Abstract The presence of a serum factor in chronic renal failure (CRF) which inhibits erythropoietin-stimulated erythropoiesis was studied, using a technique in which dog marrow cells were stimulated to produce heme in the presence of human serum. In the total series comparing 27 normal sera with 52 CRF sera, less heme was synthesized when the system contained CRF sera (total series, p = 0.0001). There was no evidence of inhibition of heme synthesis by serum from 12 patients with the anemia of chronic diseases (CD). Mixing experiments with normal and CRF sera suggested that this defect in CRF serum was not due to lack of a factor necessary for heme synthesis. Addition of urea, creatinine, and guanidinosuccinic acid to normal serum did not impair its ability to support erythropoiesis in this system. These data demonstrated that serum from patients with CRF contains a material inhibiting erythropoiesis in vitro, We propose that the material is responsible, in part, for the clinically severe anemia seen in these patients.

Variations in the Lipid Profile of Patients with Chronic Renal Failure, Treated with Folic Acid

2003 ◽  
Vol 73 (3) ◽  
pp. 215-220 ◽  
Author(s):  
de Gómez Dumm ◽  
Giammona ◽  
Touceda
Keyword(s):  
Renal Failure ◽  
Folic Acid ◽  
Chronic Renal Failure ◽  
Density Lipoprotein ◽  
Plasma Homocysteine ◽  
Lipid Profiles ◽  
Erythrocyte Membranes ◽  
Favorable Effect ◽  
High Dose ◽  
Acid Therapy

Dyslipidemia and increases in plasma homocysteine usually occur at end-stage renal disease; both are recognized as risk factors for atherosclerosis. Folate administration reduces homocysteine concentration. In this study we determined the effect of a high dose of folic acid (40 mg intravenous injection three times a week) on plasma and red blood cell lipid profiles in twelve chronic renal failure patients on regular hemodialysis. Fasting blood samples were taken at the beginning of the study (baseline) and after 21, 42, and 64 days of treatment. Folic acid supplementation decreased plasma homocysteine. Plasma triglyceride levels decreased whereas polyunsaturated fatty acid values increased after 21 days; then they returned to baseline levels at the end of treatment. Total cholesterol and low-density lipoprotein (LDL) cholesterol were higher than those of the baseline during all the study, whereas high-density lipoprotein (HDL) cholesterol was reduced. In erythrocyte membranes, folic acid therapy enhanced cholesterol/phospholipid ratios and the fluorescence anisotropy of diphenyl-hexatriene. We conclude that large doses of folic acid produce a favorable effect, reducing plasma homocysteine levels and protecting patients from atherosclerosis. However, as this therapy induces significant alterations in both plasma and erythrocyte membrane lipid profiles, plasma lipid values should be controlled throughout the treatment of patients with renal failure.

Sign in / Sign up

Export Citation Format

Share Document